Pooled tumor lysates from regorafenib- and vehicle-treated mice were analyzed for the effects of regorafenib on selected proteins involved in the MAPK and AKT/mTOR signaling pathways and for selected proteins involved in the cell cycle (Fig. 4). The gene discussed is MTOR; the disease is neoplasm.